A more thorough understanding of the interaction between TLR9+CD123+ pDCs and CTSK in OLP may lead to the development of novel pharmacologic strategies to disrupt Th17 cell differentiation as a further means of suppressing the disease progression. This evidence concerns the gene TLR9 and oral lichen planus.